Marek Jakobisiak

Summary

Country: Poland

Publications

  1. ncbi Interleukin 15 as a promising candidate for tumor immunotherapy
    Marek Jakobisiak
    Department of Immunology, Center of Biostructure Research, The Medical University of Warsaw, Poland
    Cytokine Growth Factor Rev 22:99-108. 2011
  2. ncbi Genetic modification of T cells improves the effectiveness of adoptive tumor immunotherapy
    Marek Jakobisiak
    Department of Immunology, Centre of Biostructure Research, Medical University of Warsaw, Banacha 1a, Building F, 02 097 Warsaw, Poland
    Arch Immunol Ther Exp (Warsz) 58:347-54. 2010
  3. ncbi Statins can modulate effectiveness of antitumor therapeutic modalities
    Marek Jakobisiak
    Department of Immunology, Center of Biostructure Research, The Medical University of Warsaw, Warsaw, Poland
    Med Res Rev 30:102-35. 2010
  4. ncbi CpG immunostimulatory oligodeoxynucleotide 1826 enhances antitumor effect of interleukin 12 gene-modified tumor vaccine in a melanoma model in mice
    Tomasz Switaj
    Department of Immunology, Center of Biostructure, Medical University of Warsaw, Warsaw, Poland
    Clin Cancer Res 10:4165-75. 2004
  5. ncbi Complete tumour regressions induced by vaccination with IL-12 gene-transduced tumour cells in combination with IL-15 in a melanoma model in mice
    Witold Lasek
    Department of Immunology, Centre of Biostructure, Medical University of Warsaw, Chałubińskiego 5, 02 004 Warsaw, Poland
    Cancer Immunol Immunother 53:363-72. 2004
  6. ncbi Demethylating agent 5-aza-2'-deoxycytidine enhances expression of TNFRI and promotes TNF-mediated apoptosis in vitro and in vivo
    Rafal Kaminski
    Department of Immunology, Center of Biostructure, The Medical University of Warsaw, ul Chalubinskiego 5, 02 004 Warsaw, Poland
    Oncol Rep 12:509-16. 2004
  7. ncbi Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity
    Jacek Bil
    Department of Immunology, Center of Biostructure Research, Medical University of Warsaw, 02 097 Warsaw, Poland
    Blood 115:3745-55. 2010
  8. ncbi Proteasome inhibition potentiates antitumor effects of photodynamic therapy in mice through induction of endoplasmic reticulum stress and unfolded protein response
    Angelika Szokalska
    Department of Immunology, Center of Biostructure Research, Medical University of Warsaw, Warsaw, Poland
    Cancer Res 69:4235-43. 2009
  9. ncbi Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro
    Jacek Bil
    Department of Immunology, Center of Biostructure Research, Medical University of Warsaw, Banacha 1a, F Building, 02 097 Warsaw, Poland
    Cancer Lett 288:57-67. 2010
  10. ncbi Lovastatin potentiates antitumor activity of doxorubicin in murine melanoma via an apoptosis-dependent mechanism
    Wojciech Feleszko
    Department of Immunology Center of Biostructure Research, The Medical University of Warsaw, Warsaw, Poland
    Int J Cancer 100:111-8. 2002

Collaborators

Detail Information

Publications29

  1. ncbi Interleukin 15 as a promising candidate for tumor immunotherapy
    Marek Jakobisiak
    Department of Immunology, Center of Biostructure Research, The Medical University of Warsaw, Poland
    Cytokine Growth Factor Rev 22:99-108. 2011
    ....
  2. ncbi Genetic modification of T cells improves the effectiveness of adoptive tumor immunotherapy
    Marek Jakobisiak
    Department of Immunology, Centre of Biostructure Research, Medical University of Warsaw, Banacha 1a, Building F, 02 097 Warsaw, Poland
    Arch Immunol Ther Exp (Warsz) 58:347-54. 2010
    ..Such lymphocytes could be safely and more extensively used in tumor patients because they could be eliminated should a severe graft-versus-host reaction develop...
  3. ncbi Statins can modulate effectiveness of antitumor therapeutic modalities
    Marek Jakobisiak
    Department of Immunology, Center of Biostructure Research, The Medical University of Warsaw, Warsaw, Poland
    Med Res Rev 30:102-35. 2010
    ..Most of the studies reviewed in this article have been carried in vitro or in experimental tumor models, but clinical relevance of the findings is also discussed...
  4. ncbi CpG immunostimulatory oligodeoxynucleotide 1826 enhances antitumor effect of interleukin 12 gene-modified tumor vaccine in a melanoma model in mice
    Tomasz Switaj
    Department of Immunology, Center of Biostructure, Medical University of Warsaw, Warsaw, Poland
    Clin Cancer Res 10:4165-75. 2004
    ....
  5. ncbi Complete tumour regressions induced by vaccination with IL-12 gene-transduced tumour cells in combination with IL-15 in a melanoma model in mice
    Witold Lasek
    Department of Immunology, Centre of Biostructure, Medical University of Warsaw, Chałubińskiego 5, 02 004 Warsaw, Poland
    Cancer Immunol Immunother 53:363-72. 2004
    ....
  6. ncbi Demethylating agent 5-aza-2'-deoxycytidine enhances expression of TNFRI and promotes TNF-mediated apoptosis in vitro and in vivo
    Rafal Kaminski
    Department of Immunology, Center of Biostructure, The Medical University of Warsaw, ul Chalubinskiego 5, 02 004 Warsaw, Poland
    Oncol Rep 12:509-16. 2004
    ..Altogether our studies show that the combination treatment with 5-aza-2'-deoxycytidine and TNF might be effective in the treatment of melanoma...
  7. ncbi Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity
    Jacek Bil
    Department of Immunology, Center of Biostructure Research, Medical University of Warsaw, 02 097 Warsaw, Poland
    Blood 115:3745-55. 2010
    ..These studies indicate that CD20 levels are regulated by 2 proteolytic systems and that the use of proteasome inhibitors may be associated with unexpected negative influence on R-CDC...
  8. ncbi Proteasome inhibition potentiates antitumor effects of photodynamic therapy in mice through induction of endoplasmic reticulum stress and unfolded protein response
    Angelika Szokalska
    Department of Immunology, Center of Biostructure Research, Medical University of Warsaw, Warsaw, Poland
    Cancer Res 69:4235-43. 2009
    ..The results of these studies are of immediate clinical application because bortezomib is a clinically approved drug that undergoes extensive clinical evaluations for the treatment of solid tumors...
  9. ncbi Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro
    Jacek Bil
    Department of Immunology, Center of Biostructure Research, Medical University of Warsaw, Banacha 1a, F Building, 02 097 Warsaw, Poland
    Cancer Lett 288:57-67. 2010
    ..Statins and tyrosine kinase inhibitors were used at doses that are achievable clinically, which makes the combination promising for future studies, especially in urooncology, bearing in mind possible cardiotoxic effects...
  10. ncbi Lovastatin potentiates antitumor activity of doxorubicin in murine melanoma via an apoptosis-dependent mechanism
    Wojciech Feleszko
    Department of Immunology Center of Biostructure Research, The Medical University of Warsaw, Warsaw, Poland
    Int J Cancer 100:111-8. 2002
    ..The results of our studies suggest that lovastatin may enhance the effectiveness of chemotherapeutic agents in the treatment of malignant melanomas...
  11. ncbi Interleukin 15 augments antitumor activity of cytokine gene-modified melanoma cell vaccines in a murine model
    Grzegorz W Basak
    Department of Immunology, Centre of Biostructure Research, Medical University of Warsaw, 02 097 Warsaw, Poland
    Oncol Rep 19:1173-9. 2008
    ..To our knowledge, this is the first report that shows the universal genetically-modified tumor cell vaccine-augmenting properties of IL-15. The cytokine can be useful as an adjuvant in cancer gene therapy in humans...
  12. ncbi Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo
    Tadeusz Issat
    Department of Immunology, Center of Biostructure, The Medical University of Warsaw, 02 097 Warsaw, Poland
    Int J Oncol 30:1413-25. 2007
    ..The combination of statins and pamidronate, a second generation bisphosphonate, demonstrates promising antitumor effects at doses readily achievable in patients. This combination holds promise for future clinical studies...
  13. ncbi Antitumor effects of the combination of cholesterol reducing drugs
    Tadeusz Issat
    Department of Immunology, Center of Biostructure Research, The Medical University of Warsaw, Banacha 1a, F Building, 02 097 Warsaw, Poland
    Oncol Rep 26:169-76. 2011
    ..Taking into account the number of patients treated with the investigated drugs one may suppose that the described interactions may be of clinical value...
  14. ncbi Cardiotoxicity of the anticancer therapeutic agent bortezomib
    Dominika Nowis
    Department of Immunology, Center of Biostructure Research, Medical University of Warsaw, 1a Banacha Str, F Building, 02 097 Warsaw, Poland
    Am J Pathol 176:2658-68. 2010
    ....
  15. ncbi Ciglitazone, an agonist of peroxisome proliferator-activated receptor gamma, exerts potentiated cytostatic/cytotoxic effects against tumor cells when combined with lovastatin
    Piotr Mrowka
    Department of Immunology, Center of Biostructure Research, The Medical University of Warsaw, 02 097 Warsaw, Poland
    Int J Oncol 32:249-55. 2008
    ..These results strongly suggest that combining PPAR-gamma agonists with statins can produce significant antitumor effects...
  16. ncbi Erythropoietin reduces cisplatin-induced neurotoxicity without impairment of cytotoxic effects against tumor cells
    Dominika Nowis
    Department of Immunology, Center of Biostructure Research, Medical University of Warsaw, 02 097, Warsaw, Poland
    Int J Oncol 31:1547-52. 2007
    ..Altogether our studies confirm that erythropoietin might be an effective cytoprotective agent that reduces cisplatin-induced neurotoxicity...
  17. ncbi IL-12 or IL-15, unlike IL-2, does not interact with histamine in augmenting cytotoxicity of splenocytes against melanoma cells and YAC-1 cells
    Katarzyna Kozar
    Department of Immunology, Center of Biostructure, 02-004 Warsaw, Poland
    Oncol Rep 9:427-31. 2002
    ..Further, we demonstrate that histamine-mediated potentiation of cytotoxicity is not applicable to IL-12, another potent activator of NK cell activity...
  18. ncbi A single injection of immature dendritic cells is able to induce antitumour response against a murine colon adenocarcinoma with a low apoptotic index
    Ahmad Jalili
    Department of Immunology, Center of Biostructure, The Medical University of Warsaw, Poland
    Oncol Rep 9:991-4. 2002
    ..Here we show that even a single injection of immature dendritic cells is able to induce a significant immune response against tumours with low apoptotic index...
  19. ncbi Antitumor effects of photodynamic therapy are potentiated by 2-methoxyestradiol. A superoxide dismutase inhibitor
    Jakub Golab
    Department of Immunology, The Medical University of Warsaw, 02 004 Warsaw, Poland
    J Biol Chem 278:407-14. 2003
    ..We conclude that inhibition of MnSOD activity by 2-MeOE(2) is an effective treatment modality capable of potentiating the antitumor effectiveness of PDT...
  20. ncbi Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines
    Wojciech Feleszko
    Department of Immunology, Centre of Biostructure Research, The Medical University of Warsaw, Poland
    Oncol Rep 9:879-85. 2002
    ..5-fold in colon-26 cancer cells. Combination of a specific COX-2 inhibitor, MF-tricyclic, may increase antiproliferative effects of lovastatin in colon cancer cells and this effect was due to an augmented apoptosis...
  21. ncbi Statins impair antitumor effects of rituximab by inducing conformational changes of CD20
    Magdalena Winiarska
    Department of Immunology, Center of Biostructure Research, The Medical University of Warsaw, Warsaw, Poland
    PLoS Med 5:e64. 2008
    ..The objective of this study was to evaluate the influence of statins on rituximab-induced killing of B cell lymphomas...
  22. ncbi AAF-cmk sensitizes tumor cells to trail-mediated apoptosis
    Izabela Młnarczuk
    Department of Immunology, Center of Biostructure, The Medical University of Warsaw, Chalubinskiego 5, 02004 Warsaw, Poland
    Leuk Res 28:53-61. 2004
    ..Altogether, our studies indicate that AAF-cmk might effectively sensitize human leukemia cells to apoptosis induced by TRAIL and TNF...
  23. ncbi Statins impair glucose uptake in tumor cells
    Agata Malenda
    Department of Immunology, Center of Biostructure Research, Medical University of Warsaw, Warsaw, Poland
    Neoplasia 14:311-23. 2012
    ..By inhibiting (18)F-FDG uptake, statins can negatively affect the sensitivity of positron emission tomography, a diagnostic procedure frequently used in oncology...
  24. ncbi Potentiated antitumor effects of a combination therapy with a farnesyltransferase inhibitor L-744,832 and butyrate in vitro
    Maciej Kopec
    Department of Immunology, Centre of Biostructure Research, The Medical University of Warsaw, 02-004 Warsaw, Poland
    Oncol Rep 11:1127-31. 2004
    ..In MIA PaCa-2 cells, the combination therapy exerted additive antitumor activity. Our results illustrate possible application of the farnesyltransferase inhibitor L-744,832 and butyrate as a combination therapy of cancer...
  25. ncbi Potential antitumor effects of statins (Review)
    Marek Jakobisiak
    Department of Immunology, Center of Biostructure, The Medical University of Warsaw, 02 004 Warsaw, Poland
    Int J Oncol 23:1055-69. 2003
    ....
  26. ncbi Erythropoietin restores the antitumor effectiveness of photodynamic therapy in mice with chemotherapy-induced anemia
    Jakub Gołąb
    Department of Immunology, Center of Biostructure, The Medical University of Warsaw, 02 004, Poland
    Clin Cancer Res 8:1265-70. 2002
    ..The study was designed to examine the impact of anemia on the antitumor efficacy of photodynamic therapy (PDT) in a murine colon-26 adenocarcinoma model syngeneic with BALB/c mice...
  27. ncbi Natural mechanisms protecting against cancer
    Marek Jakobisiak
    Department of Immunology, Center of Biostructure, The Medical University of Warsaw, Chalubinskiego 5, 02 004 Warsaw, Poland
    Immunol Lett 90:103-22. 2003
    ..Many cytokines belonging to different families display anti-tumor activity but their role in natural anti-tumor defense remains largely to be established...
  28. ncbi Potentiated antitumor effects of butyrate and actinomycin D in melanoma model in mice
    Adam Giermasz
    Department of Immunology, Center of Biostructure Research, The Medical University of Warsaw, 02-004 Warsaw, Poland
    Oncol Rep 9:199-203. 2002
    ..The results illustrate also the possible application of this combination in cancer therapy...
  29. ncbi Synergistic antitumor effect of JAWSII dendritic cells and interleukin 12 in a melanoma mouse model
    Łukasz Zapała
    Department of Immunology, Centre of Biostructure Research, Medical University of Warsaw, 02 097 Warsaw, Poland
    Oncol Rep 29:1208-14. 2013
    ..The results of the study may be helpful in planning optimal DC-based therapeutic protocols in cancer patients...